Gregory Mishkel, MD
Cardiovascular Disease · Skokie, ILNPI 1629150768
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Heartflow, Inc. at 59.2% of the total. Reporting peaked in 2023 at $19,443 and has fallen 97.7% since, to $439 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $417.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$27K
- Siemens Medical Solutions USA, Inc.$12K
- Boston Scientific$3K
- Abbott$871
- GE HealthCare$531
- Shockwave Medical, Inc$325
- plus $1K from 12 others
Across 32 payments — averaging $1197.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$38K
What the payments were for
- Consulting fees$20,38845%
- Speaking & faculty fees$7,91318%
- Travel & lodging$11,41425%
- Food & beverage$5,32812%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 21 | $26,696 |
| Siemens Medical Solutions USA, Inc. | 32 | $12,141 |
| Boston Scientific | 11 | $3,207 |
| Abbott | 10 | $871 |
| GE HealthCare | 7 | $531 |
| Shockwave Medical, Inc | 3 | $325 |
| Edwards Lifesciences | 4 | $317 |
| Amgen | 3 | $292 |
| Medtronic(2 entities) | 5 | $247 |
| Novo Nordisk | 2 | $180 |
| Actelion Pharmaceuticals US, Inc. | 2 | $60 |
| Akcea Therapeutics, Inc. | 1 | $52 |
| Boehringer Ingelheim | 2 | $37 |
| Abiomed | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| LSI Solutions Inc | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$25,708
- GENERAL - THERAPIES$1,862
- NAEOTOM Alpha$1,180
- Artis icono floor$759
- Mitra Clip system$279
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$272
- GENERAL - STRUCTURAL HEART$241
- CorPath Imaging System$237
- syngo dynamics$183
- SOMATOM Force$174
- Repatha$150
- MAGNETOM Sola$146
- COROFLOW$141
- SAPIEN 3 Ultra RESILIA$132
- Confirm Rx$119
- Perclose ProStyle$117
- Watchman$103
How this compares
$45,059 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 188 | $186,854 |
| JardianceEmpagliflozin | 73 | $73,123 |
| XareltoRivaroxaban | 45 | $50,694 |
| EntrestoSacubitril/Valsartan | 38 | $43,335 |
| MounjaroTirzepatide | 26 | $29,768 |
| OzempicSemaglutide | 22 | $23,426 |
| FarxigaDapagliflozin Propanediol | 18 | $11,373 |
| Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid | 11 | $4,337 |
| Rosuvastatin Calcium | 130 | $2,508 |
| Atorvastatin Calcium | 187 | $2,312 |
| Metoprolol Succinate | 109 | $1,966 |
| Telmisartan | 53 | $1,661 |
| Ezetimibe | 66 | $1,559 |
| Eplerenone | 23 | $1,514 |
| Candesartan Cilexetil | 16 | $1,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $37 | $73,12373 claims |
| Johnson & JohnsonXarelto | $17 | $50,69445 claims |
| Novo NordiskOzempic | $180 | $23,42622 claims |
| AstraZenecaFarxiga | $14 | $11,37318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Skokie
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
- Robert KochLibertyville$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.